The upgrade from Neutral to Buy by Citigroup indicates a positive outlook for Ionis Pharmaceuticals. The raised price target from $36 to $60 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and potentially a rise in the stock price in the short term.